Dioscin (Synonyms: 薯蓣皂甙; Collettiside III; CCRIS 4123)

目录号: HY-N0124 纯度: 99.95%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

Dioscin (CCRIS 4123; Collettiside III) 是天然的植物来源的甾体皂苷，针对多种癌细胞有较好的抗癌活性。Dioscin 可造成 HeLa 和 SiHa 细胞的 DNA 损伤，并诱导细胞凋亡 (apoptosis)。Dioscin 调节 ROS 介导的 DNA 损伤和线粒体信号通路，发挥抗癌活性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Dioscin Chemical Structure

CAS No. : 19057-60-4

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥459	In-stock
5 mg	￥400	In-stock
10 mg	￥480	In-stock
25 mg	￥624	In-stock
50 mg	￥748	In-stock
100 mg	￥898	In-stock
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Dioscin:

Dioscin (Standard) 询价

MCE 顾客使用本产品发表的 10 篇科研文献

: Dioscin purchased from MCE. Usage Cited in: Int Immunopharmacol. 2023 Feb 19;117:109839. [Abstract]; Dioscin-Medium group (5 mg/kg; p.o.; every-two days for 12 weeks) profoundly inhibits the phosphorylation of NF-ĸB in mice (Fig H and I). Dioscin-Low (Dio-L, 2.5 mg/kg), Dioscin-Medium (Dio-M, 5 mg/kg) and Dioscin-High (Dio-H, 10 mg/Kg).

: Dioscin purchased from MCE. Usage Cited in: Mol Med Rep. 2017 Oct;16(4):4922-4926. [Abstract]; Dioscin concentrations of 0.5, 1, 5, 10 and 25 µg/mL promotes the expression of ALP and inhibits the expression of LC3B in MC3T3-E1 cells, in a concentration-dependent manner.

Dioscin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

Dioscin (CCRIS 4123; Collettiside III) is a natural plant-derived steroidal saponin that has good anti-cancer activity against a variety of cancer cells. Dioscin causes DNA damage and induces apoptosis in HeLa and SiHa cells. Dioscin regulates ROS-mediated DNA damage and mitochondrial signaling pathways, exerting anticancer activity^[1]^[2]^[3]^[4]^[5]^[6].

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.581 μM Compound: Dioscin	Cytotoxicity against human A2780 cells by MTT assay Cytotoxicity against human A2780 cells by MTT assay	[PMID: 21482468]
A2780	IC₅₀	0.87 μM Compound: Dioscin	Cytotoxicity against human A2780 cells by MTT assay Cytotoxicity against human A2780 cells by MTT assay	[PMID: 22429911]
A2780	IC₅₀	4.46 μM Compound: Dioscin	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 19362474]
A549	IC₅₀	0.454 μM Compound: Dioscin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 21482468]
A549	IC₅₀	0.7 μM Compound: Dioscin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19362474]
A549	IC₅₀	0.81 μM Compound: Dioscin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 22429911]
A549	IC₅₀	4.2 μM Compound: dioscin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 16905317]
BC1 cell line	IC₅₀	3.8 μM Compound: 2	Cytotoxicity against human BC1 cells after 72 hrs by SRB assay Cytotoxicity against human BC1 cells after 72 hrs by SRB assay	[PMID: 12088425]
Bel-7402	IC₅₀	0.23 μM Compound: Dioscin	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 19362474]
Bel-7402	IC₅₀	0.81 μM Compound: Dioscin	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 22429911]
Bel-7402	IC₅₀	0.93 μM Compound: Dioscin	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 21482468]
BGC-823	IC₅₀	0.268 μM Compound: Dioscin	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 21482468]
BGC-823	IC₅₀	1.08 μM Compound: Dioscin	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 22429911]
BGC-823	IC₅₀	2 μM Compound: dioscin	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 16905317]
BXPC-3	IC₅₀	0.7 μM Compound: Dioscin	Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 19362474]
BXPC-3	GI₅₀	1.3 μg/mL Compound: 4, dioscin	Growth inhibition of humanBxPC3 cells after 48 hrs Growth inhibition of humanBxPC3 cells after 48 hrs	[PMID: 15921418]
Capan-2	IC₅₀	0.05 μM Compound: Dioscin	Cytotoxicity against human Capan2 cells after 72 hrs by MTT assay Cytotoxicity against human Capan2 cells after 72 hrs by MTT assay	[PMID: 19362474]
Col2	IC₅₀	2.8 μM Compound: 2	Cytotoxicity against human Col2 cells after 72 hrs by SRB assay Cytotoxicity against human Col2 cells after 72 hrs by SRB assay	[PMID: 12088425]
DU-145	GI₅₀	> 10 μg/mL Compound: 4, dioscin	Growth inhibition of human DU145 cells after 48 hrs Growth inhibition of human DU145 cells after 48 hrs	[PMID: 15921418]
HCT-8	IC₅₀	0.34 μM Compound: Dioscin	Cytotoxicity against human HCT8 cells by MTT assay Cytotoxicity against human HCT8 cells by MTT assay	[PMID: 22429911]
HCT-8	IC₅₀	0.351 μM Compound: Dioscin	Cytotoxicity against human HCT8 cells by MTT assay Cytotoxicity against human HCT8 cells by MTT assay	[PMID: 21482468]
HCT-8	IC₅₀	0.56 μM Compound: Dioscin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 19362474]
HeLa	IC₅₀	0.5 μM Compound: Dioscin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 22429911]
HGC-27	IC₅₀	5.9 μM Compound: dioscin	Cytotoxicity against human HGC27 cells by MTT assay Cytotoxicity against human HGC27 cells by MTT assay	[PMID: 16905317]
HL-60	IC₅₀	2 μM Compound: 6	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 12828464]
HL-60	IC₅₀	3.8 μM Compound: 1	Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 22405922]
K562	IC₅₀	4.7 μM Compound: 1	Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 23621869]
K562/Adr	IC₅₀	3.3 μM Compound: 1	Cytotoxicity against human K562/ADR cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human K562/ADR cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 23621869]
KB	IC₅₀	0.53 μM Compound: Dioscin	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 22429911]
KB	IC₅₀	20.7 μM Compound: 2	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 12088425]
KB	ED₅₀	21 μM Compound: 8	Growth inhibition of human KB cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test Growth inhibition of human KB cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test	[PMID: 19161316]
KB-V1	IC₅₀	> 23 μM Compound: 2	Cytotoxicity against human KBV1 cells after 72 hrs by SRB assay Cytotoxicity against human KBV1 cells after 72 hrs by SRB assay	[PMID: 12088425]
KETR3	IC₅₀	0.447 μM Compound: Dioscin	Cytotoxicity against human Ketr3 cells by MTT assay Cytotoxicity against human Ketr3 cells by MTT assay	[PMID: 21482468]
KM-20L2	GI₅₀	1.3 μg/mL Compound: 4, dioscin	Growth inhibition of human KM20L2 cells after 48 hrs Growth inhibition of human KM20L2 cells after 48 hrs	[PMID: 15921418]
LNCaP	IC₅₀	1.7 μM Compound: 2	Cytotoxicity against human LNCAP cells after 72 hrs by SRB assay Cytotoxicity against human LNCAP cells after 72 hrs by SRB assay	[PMID: 12088425]
LNCaP	ED₅₀	1.7 μM Compound: 8	Growth inhibition of human LNCAP cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test Growth inhibition of human LNCAP cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test	[PMID: 19161316]
Lu1	IC₅₀	1.2 μM Compound: 2	Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay	[PMID: 12088425]
Lu1	ED₅₀	1.2 μM Compound: 8	Growth inhibition of human Lu1 cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test Growth inhibition of human Lu1 cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test	[PMID: 19161316]
MCF7	GI₅₀	0.68 μg/mL Compound: 4, dioscin	Growth inhibition of human MCF7 cells after 48 hrs Growth inhibition of human MCF7 cells after 48 hrs	[PMID: 15921418]
MCF7	IC₅₀	0.879 μM Compound: Dioscin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 21482468]
MCF7	IC₅₀	1.03 μM Compound: Dioscin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19362474]
MCF7	IC₅₀	22.4 μM Compound: 2	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 12088425]
NCI-H460	GI₅₀	1.8 μg/mL Compound: 4, dioscin	Growth inhibition of human NCI-H460 cells after 48 hrs Growth inhibition of human NCI-H460 cells after 48 hrs	[PMID: 15921418]
NCI-H460	IC₅₀	4.56 μM Compound: 12	Cytotoxicity against human NCI-H460 cells incubated for 24 hrs by MTT assay Cytotoxicity against human NCI-H460 cells incubated for 24 hrs by MTT assay	[PMID: 28606759]
P388	ED₅₀	> 10 μg/mL Compound: 4, dioscin	Growth inhibition of mouse P388 cells after 48 hrs Growth inhibition of mouse P388 cells after 48 hrs	[PMID: 15921418]
P388	IC₅₀	21.9 μM Compound: 2	Cytotoxicity against mouse P388 cells after 72 hrs by SRB assay Cytotoxicity against mouse P388 cells after 72 hrs by SRB assay	[PMID: 12088425]
PANC-1	IC₅₀	0.81 μM Compound: Dioscin	Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay	[PMID: 19362474]
SF-268	GI₅₀	1.2 μg/mL Compound: 4, dioscin	Growth inhibition of human SF268 cells after 48 hrs Growth inhibition of human SF268 cells after 48 hrs	[PMID: 15921418]
SK-MEL-2	IC₅₀	1.8 μM Compound: 2	Cytotoxicity against human SK-MEL-2 cells after 72 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells after 72 hrs by SRB assay	[PMID: 12088425]
SW1990	IC₅₀	0.5 μM Compound: Dioscin	Cytotoxicity against human SW1990 cells after 72 hrs by MTT assay Cytotoxicity against human SW1990 cells after 72 hrs by MTT assay	[PMID: 19362474]
SW626	IC₅₀	3.1 μM Compound: 2	Cytotoxicity against human SW626 cells after 72 hrs by SRB assay Cytotoxicity against human SW626 cells after 72 hrs by SRB assay	[PMID: 12088425]

体外研究
(In Vitro)

Dioscin (1.25-5 μg/mL; 6-24 h) 增加 HeLa 和 SiHa 细胞内钙离子水平，并诱导细胞凋亡^[4]。
Dioscin (1.25-5 μg/mL; 6-24 h) Dioscin 上调 Bak、Bax、Bid、p53、caspase-3、caspase-9 的蛋白水平，并下调 Bcl-2 和 Bcl-xl 的蛋白水平^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Dioscin (75-300 mg/kg, 10 mL/kg; oral gavage；90 天) 对雌性大鼠无亚慢性毒性，对雄性大鼠有轻微的亚慢性毒性。Dioscin 造成雄性大鼠轻微的胃肠道扩张，并且在血液学评估中表现出溶血性贫血^[5]。
Dioscin 通过抑制氧化-硝化应激、炎症和细胞凋亡，可减轻大鼠肝缺血再灌注损伤^[6]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

869.04

Formula

C₄₅H₇₂O₁₆

CAS 号

19057-60-4

性状

固体

颜色

White to off-white

中文名称

薯蓣皂甙；薯蓣皂甙；薯蓣皂苷

结构分类

Steroids

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 100 mg/mL (115.07 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.1507 mL	5.7535 mL	11.5070 mL
5 mM	0.2301 mL	1.1507 mL	2.3014 mL
10 mM	0.1151 mL	0.5753 mL	1.1507 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.25 mg/mL (2.59 mM); 澄清溶液

此方案可获得 ≥ 2.25 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 22.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.25 mg/mL (2.59 mM); 澄清溶液

此方案可获得 ≥ 2.25 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 22.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.25 mg/mL (2.59 mM); 澄清溶液

此方案可获得 ≥ 2.25 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 22.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： 0.5% CMC-Na/saline water
Solubility: 5 mg/mL (5.75 mM); 悬浊液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.95%

选择批次：

Data Sheet (644 KB) SDS (393 KB)

COA (293 KB) HNMR (340 KB) RP-HPLC (213 KB) MS (69 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Chen J, et al. Dioscin-induced apoptosis of human LNCaP prostate carcinoma cells through activation of caspase-3 and modulation of Bcl-2 protein family. J Huazhong Univ Sci Technolog Med Sci. 2014 Feb;34(1):125-30. [Content Brief]

[2]. Qu X, et al. Dioscin inhibits osteoclast differentiation and bone resorption though down-regulating the Akt signaling cascades. Biochem Biophys Res Commun. 2014 Jan 10;443(2):658-65. [Content Brief]

[3]. Qin J, et al. Dioscin prevents the mitochondrial apoptosis and attenuates oxidative stress in cardiac H9c2 cells. Drug Res (Stuttg). 2014 Jan;64(1):47-52. [Content Brief]

[4]. Zhao X, et al. Dioscin Induces Apoptosis in Human Cervical Carcinoma HeLa and SiHa Cells through ROS-Mediated DNA Damage and the Mitochondrial Signaling Pathway. Molecules. 2016 Jun 4;21(6):730. [Content Brief]

[5]. Xu T, et al. A 90-day subchronic toxicological assessment of dioscin, a natural steroid saponin, in Sprague-Dawley rats. Food Chem Toxicol. 2012 May;50(5):1279-87. [Content Brief]

[6]. Tao X, et al. Dioscin attenuates hepatic ischemia-reperfusion injury in rats through inhibition of oxidative-nitrative stress, inflammation and apoptosis. Transplantation. 2014 Sep 27;98(6):604-11. [Content Brief]

Dioscin 相关分类

Cancer

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.1507 mL	5.7535 mL	11.5070 mL	28.7674 mL
	5 mM	0.2301 mL	1.1507 mL	2.3014 mL	5.7535 mL
	10 mM	0.1151 mL	0.5753 mL	1.1507 mL	2.8767 mL
	15 mM	0.0767 mL	0.3836 mL	0.7671 mL	1.9178 mL
	20 mM	0.0575 mL	0.2877 mL	0.5753 mL	1.4384 mL
	25 mM	0.0460 mL	0.2301 mL	0.4603 mL	1.1507 mL
	30 mM	0.0384 mL	0.1918 mL	0.3836 mL	0.9589 mL
	40 mM	0.0288 mL	0.1438 mL	0.2877 mL	0.7192 mL
	50 mM	0.0230 mL	0.1151 mL	0.2301 mL	0.5753 mL
	60 mM	0.0192 mL	0.0959 mL	0.1918 mL	0.4795 mL
	80 mM	0.0144 mL	0.0719 mL	0.1438 mL	0.3596 mL
	100 mM	0.0115 mL	0.0575 mL	0.1151 mL	0.2877 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Dioscin (Synonyms: 薯蓣皂甙; Collettiside III; CCRIS 4123)

Customer Review

Other Forms of Dioscin:

MCE 顾客使用本产品发表的 10 篇科研文献

Dioscin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Dioscin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Dioscin (Synonyms: 薯蓣皂甙; Collettiside III; CCRIS 4123)

Customer Review

Other Forms of Dioscin:

Dioscin 相关抗体

MCE 顾客使用本产品发表的 10 篇科研文献

Dioscin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

Dioscin 相关抗体:

摩尔计算器

稀释计算器

Dioscin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z